Potential antitumor activity of digitoxin and user-designed analog administered to human lung cancer cells

• Published in: Biochimica et biophysica acta. General subjects Vol. 1864; no. 11; p. 129683
• Main Authors: Eldawud, Reem, Wagner, Alixandra, Dong, Chenbo, Gupta, Neha, Rojanasakul, Yon, O'Doherty, George, Stueckle, Todd A., Dinu, Cerasela Zoica
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2020
• Subjects: adhesion; Anti-tumor activity; antineoplastic activity; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; apoptosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Cardiac glycosides; Cell Line, Tumor; Cell Movement - drug effects; cell proliferation; Chemotherapy; Cytoskeleton - drug effects; Cytoskeleton - pathology; Digitoxin; Digitoxin - analogs & derivatives; Digitoxin - pharmacology; dose response; epithelium; focal adhesions; gene expression; genes; heart failure; human diseases; Humans; Lung cancer; lung neoplasms; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; lungs; metalloproteinases; microtubules; neoplasm cells; non-specific serine/threonine protein kinase; protein synthesis; signal transduction; Synthetic analog; Therapeutic alternatives; therapeutics; toxicity; BCA; CG; E; Lung cancer; Anti-tumor activity; DEG; AFM; ECIS; DTX; Therapeutic alternatives; Synthetic analog; Cardiac glycosides; MFI; Chemotherapy; Digitoxin; D6MA

Cardiac glycosides (CGs), such as digitoxin, are traditionally used for treatment of congestive heart failure; recently they also gained attention for their anticancer properties. Previous studies showed that digitoxin and a synthetic L-sugar monosaccharide analog treatment decreases cancer cell pro...